When it comes to programmed cell death (PCD), apoptosis is usually the first process that comes to mind. However, there is a new type of inflammatory PCD discovered in 2012, known as ferroptosis, that is genetically and biochemically distinct from other PCD.¹

Anyone who is remotely interested in biology, or has perhaps scrolled through fitness websites to get in shape, has come across the word "protein". There is, however, much more to proteins than simply being a key player in maintaining active lifestyles. Proteins are ubiquitous in the cells of the body and are the driving force for key cellular processes. In order for proteins to carry out their duties, they need to be well-armed to execute their functions. This process of making the protein competent is achieved through specific post translational modifications (PTMs). The star of the PTMs is a cellular process called phosphorylation. The conventional methods adopted for quantifying phosphorylation are highly labor intensive. The development of phospho-specific antibodies has allowed for a huge sigh of relief from researchers due to their reputation of being quick, and detecting only phosphorylated forms of proteins in a complex mixture of phosphorylated and non-phosphorylated forms.

The advancement of recombinant DNA technology in recent years has drastically changed the world of research by controlling the expressions of target genes. Recombinant DNA combines genetic material from different sources, creating sequences that are unique and new to the genome. The DNA sequences used in the construction of recombinant DNA molecules can originate from any species, such as human, fungal, bacterial, and plants. ¹

This has been an incredibly exciting past few days in the world of scientific research. For those unfamiliar, the 2020 Nobel Prize winners are set to be announced this week; as of today’s writing on October 7th, 2020, three sets of award winners have already been unveiled in medicine, physics, and chemistry. Today, we’ll take a closer look at the backgrounds and distinguished research of the laureates in medicine.

In a press release on August 26th, 2020, Abbott Laboratories announced that they were issued an emergency use authorization (EUA) by the FDA for their new, rapid point-of-care COVID-19 antigen test. Branded as the “BinaxNOW COVID-19 Ag Card”, the test is unique compared to the more prevalent molecular-based detection tests for COVID-19 in that it utilizes a lateral flow assay, similar to traditional over-the-counter pregnancy tests. Contained in a portable, credit-card sized device, Abbott claims that the test can deliver results in as little as 15 minutes, representing a significant reduction in time compared to RT-PCR-based tests that have turnaround times on a scale of hours rather than minutes.

For the first installment of our ABclonal Webinar Series on August 26th, we had the privilege of inviting Dr. Yong Xu of the Baylor College of Medicine to share his research on neuroendocrine mechanisms for appetite regulation and their implications on conditions such as obesity. If you were unable to attend the live session or would like to re-watch to review some of Dr. Xu's key points, we've got you covered with a link to a recording of the webinar and Q&A here, as well as recap of his lecture below.